Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Characteristics and outcomes of COVID-19 patients admitted to hospital with and without respiratory symptoms.

Citarella BW. et al, (2024), Heliyon, 10

A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity.

Liu C. et al, (2024), Cell Rep Med, 5

Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.

Goodyear CS. et al, (2024), Lancet Rheumatol

MAIT cell-MR1 reactivity is highly conserved across multiple divergent species.

Edmans MD. et al, (2024), J Biol Chem

Antibody, not Cellular, Immune Responses to SARS-CoV-2 Vaccination Outperform Infection in Inflammatory Bowel Disease Patients.

González Cueto E. et al, (2024), Inflamm Bowel Dis, 30, 859 - 862

Fine needle aspiration of human lymph nodes reveals cell populations and soluble interactors pivotal to immunological priming.

Provine NM. et al, (2024), Eur J Immunol, 54

Neurodegenerative fluid biomarkers are enriched in human cervical lymph nodes

Al-Diwani A. et al, (2024)

Multi-omics analysis reveals COVID-19 vaccine induced attenuation of inflammatory responses during breakthrough disease.

Drury RE. et al, (2024), Nat Commun, 15

Obesity Differs from Diabetes Mellitus in Antibody and T Cell Responses Post COVID-19 Recovery.

Ali M. et al, (2024), Clin Exp Immunol

Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection.

Liu C. et al, (2024), Nat Commun, 15

Southeast Asia initiative to combat SARS-CoV-2 variants (SEACOVARIANTS) consortium

Nhu LNT. et al, (2024), Wellcome Open Research, 9, 181 - 181

The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86.

Zhou D. et al, (2024), Nat Commun, 15

IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma.

Luo J. et al, (2024), Mucosal Immunol

A single cell atlas of frozen shoulder capsule identifies features associated with inflammatory fibrosis resolution.

Ng MTH. et al, (2024), Nat Commun, 15

Cohort Profile: Post-Hospitalisation COVID-19 (PHOSP-COVID) study

Elneima O. et al, (2024), International Journal of Epidemiology, 53

Emerging Enterovirus A71 Subgenogroup B5 Causing Severe Hand, Foot, and Mouth Disease, Vietnam, 2023.

Chau NVV. et al, (2024), Emerg Infect Dis, 30, 363 - 367

Pre-existing asthma as a comorbidity does not modify cytokine responses and severity of COVID-19

Luo J. et al, (2024)

Accelarated immune ageing is associated with COVID-19 disease severity.

Lord JM. et al, (2024), Immun Ageing, 21

MAIT cells protect against sterile lung injury

Zhang X. et al, (2024)

Effect of second booster vaccinations and prior infection against SARS-CoV-2 in the UK SIREN healthcare worker cohort.

Kirwan PD. et al, (2024), Lancet Reg Health Eur, 36

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?